Clarivate acquires Bioinfogate

Clarivate has acquired Bioinfogate, furthering our goal to provide end-to-end solutions for life sciences companies along the entire drug development lifecycle. This combination will provide critical translational safety intelligence alongside robust drug pipeline and preclinical research information. This allows biopharma to seamlessly integrate safety intelligence into preclinical research, clinical trial planning, regulatory and pharmacovigilance monitoring, and portfolio strategy – ultimately enabling them to quickly and safely bring lifesaving drugs to patients.

Together, Clarivate and Bioinfogate have the power to provide:

• New offerings: OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery and Cortellis Competitive Intelligence. We are actively looking for ways to continue to expand and integrate this critical content into all aspects of the life science cycle. Near-term plans include additional integration with Cortellis Drug Discovery Intelligence as well as integration with Metacore (i.e., links to and from OFF-X).
• Filling the gap of safety intelligence: The acquisition of Bioinfogate fills a critical gap in our portfolio for drug toxicity data will link translational safety intelligence across all stages of drug R&D. Offering integrated solutions will enable biopharma to monitor safety liabilities, benchmark safety profiles and detect adverse events of new and existing compounds across all stages of drug R&D.
• Continued exceptional value: We will continue to create exceptional value for our customers through new offerings focused on further integrating the drug development information found in Cortellis with the translational safety intelligence from OFF-X. These new holistic solutions will further allow biopharma to make confident, data-driven decisions along the entire drug lifecycle, ultimately enabling them to quickly and safely bring lifesaving drugs to patients.

There is no change to any product or service you currently receive from either company. Our goal will be to identify ways to enhance our current products and services, as well as introduce new services that will improve your daily operations.

Bioinfogate’s OFF-X portal is a cutting-edge safety intelligence solution aimed at empowering pharmaceutical organizations to identify toxicology and safety issues, mitigate safety liabilities and de-risk early-stage assets.

Through a 2019 partnership with Bioinfogate, OFF-X is already integrated with several Clarivate products, including Cortellis Drug Discovery and Cortellis Competitive Intelligence. This acquisition enables Clarivate to continue to expand and integrate this critical content into all aspects of the life science cycle.

This is the second acquisition from the Prous family of companies. The Integrity product was acquired from Prous Science in 2007 and is now known as Cortellis Drug Discovery Intelligence™.

The acquisition is very positive for our customers. With the addition of Bioinfogate to the Clarivate family, we can continue to create exceptional value for our customers through new offerings focused on further integrating the drug development information found in Cortellis with the translational safety intelligence from OFF-X

Our priority is, and will remain, to ensure that we are providing the best tools, analysis and innovation. This acquisition will enable us to take that commitment to the next level and be an even more valuable resource for our customers.

Clarivate has acquired Bioinfogate, furthering our goal to provide end-to-end solutions for life sciences companies along the entire drug development lifecycle. This combination will provide critical translational safety intelligence alongside robust drug pipeline and preclinical research information. This allows biopharma to seamlessly integrate safety intelligence into preclinical research, clinical trial planning, regulatory and pharmacovigilance monitoring, and portfolio strategy – ultimately enabling them to quickly and safely bring lifesaving drugs to patients.

Together, Clarivate and Bioinfogate have the power to provide:

• New offerings: OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery and Cortellis Competitive Intelligence. We are actively looking for ways to continue to expand and integrate this critical content into all aspects of the life science cycle. Near-term plans include additional integration with Cortellis Drug Discovery Intelligence as well as integration with Metacore (i.e., links to and from OFF-X).
• Filling the gap of safety intelligence: The acquisition of Bioinfogate fills a critical gap in our portfolio for drug toxicity data will link translational safety intelligence across all stages of drug R&D. Offering integrated solutions will enable biopharma to monitor safety liabilities, benchmark safety profiles and detect adverse events of new and existing compounds across all stages of drug R&D.
• Continued exceptional value: We will continue to create exceptional value for our customers through new offerings focused on further integrating the drug development information found in Cortellis with the translational safety intelligence from OFF-X. These new holistic solutions will further allow biopharma to make confident, data-driven decisions along the entire drug lifecycle, ultimately enabling them to quickly and safely bring lifesaving drugs to patients.

There are no immediate changes to the Bioinfogate OFF-X portal. Moving forward, we will look for ways to further integrate and enhance Cortelils and OFF-X, as well as introduce new offerings that will improve your daily operations.

Clarivate has a mission is to accelerate the pace of innovation by providing trusted insights and analytics to customers around the world, which could make a real difference – whether that’s finding the cure for cancer or delivering the first successful self-driving car.

Clarivate has a collection of leading subscription-based businesses focused in different areas including: scientific and academic research; patent analytics and regulatory standards; pharmaceutical and biotech intelligence; trademark protection; domain brand protection and intellectual property management.

Clarivate is a public company, traded on the NYSE under the symbol CLVT.

This acquisition is well-aligned to our mission, and will help us to advance medical sciences, from research to outcome, offering a one-stop shop for life science customers and help them to improve human lives.

The acquisition is very positive for our customers. With the addition of Bioinfogate to the Clarivate family, we can continue to create exceptional value for our customers through new offerings focused on further integrating the drug development information found in Cortellis with the translational safety intelligence from OFF-X.